Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

2607 - The potential protective effect of exogenous antioxidant “L-Carnosine” on Oxaliplatin- Induced Peripheral Neuropathy in colorectal cancer patients; A perspective on targeting Nrf 2 and NF-κB pathway.


10 Sep 2017


Poster display session


Rana Yehia


R. Yehia1, N.M. Sarhan1, M. Schaalan1, A.S. Shafik2, S. Saleh3, H. Elabhar3

Author affiliations

  • 1 Clinical Pharmacy, Misr International University, 11311 - Cairo/EG
  • 2 Clinical Oncology, Ain Shams University, 002 - Cairo/EG
  • 3 Pharmacology, Cairo University, Cairo/EG


Abstract 2607


Chemotherapy-induced peripheral neuropathy is a common side effect afflicting patients with cancer treated with neurotoxic chemotherapeutic agents, as oxalipatin. Aim: The study aims at investigating the use of anti-oxidant L-carnosine for prevention of acute oxaliplatin neurotoxicity in colorectal cancer patients by assessing its effect on Nuclear factor-2 erythroid related factor-2 (Nrf2) induced oxidative stress pathways by assessment of serum levels of Malondialdehyde (MDA), Nuclear factor-kappa light chain enhancer of B cells (NF-κB) anti-inflammatory pathway and pro-apoptotic signals Caspase-3 (Casp-3).


In this pilot study 65 patients were recruited using prospective randomized controlled study design and enrolled randomly into to two arms; Arm A (31 patients) received FOLFOX-6 regimen (oxaliplatin, 5FU & leucovorin) and Arm B (34 patients) received FOLFOX-6 regimen and oral L-carnosine 500 mg daily all along the treatment. All recruited patients were followed up for three months, then both arms were analyzed for neuropathy incidence/grade and any additional toxicities according to NCI-CTC version 4.


In both arms the correlation analysis was significantly positive between NF-κ B and either Nrf2 and caspase 3.

Concerning the improving impact of L-Carnosine added to oxaliplatin, represented in Arm B, on inflammatory markers, it caused a significant decrease in the levels of NFkB (27%) compared to Arm A. Intriguingly, this ameliorative anti-inflammatory effect of L-Carnosine was also reflected on its anti-apoptotic and anti-oxidative effects, by reducing caspase activity (49%), MDA level (51.8%) as well as significant elevation of Nrf2 (38.7%), compared to Arm A.


Dietary supplementation with L-Carnosine proved to improve Oxalipaltin induced peripheral neuropathy by amelioration of the pathophysiologic triad of inflammation, oxidative stress and apoptosis. These results led to the recommendation of safe add-on therapy of Carnosine to chemotherapeutic agents, and opens thereby, a new supportive strategy in oncologic diseases.

Clinical trial identification


This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.